C8 MediSensors, a developer of non-invasive continuous glucose monitoring solution for diabetes management, has announced that it has filed for CE market certification required for marketing its C8 MediSensors Optical Glucose Monitor in the Europe Union.
C8 MediSensors Optical Glucose Monitor with Smartphone report view
The C8 MediSensors Optical monitor is an adjunct investigational device and features a light-sensitive sensor to measure the glucose level in a non-invasive, pain-free manner. Unlike invasive, continuous glucose monitors available in the market, the C8 MediSensors monitor does not need to be recalibration to maintain accuracy.
The Chief Operating Officer of C8 MediSensors, Paul S. Zygielbaum stated that the there are more than 300 million diabetic patients in the European Union who require continuous glucose monitoring. The invasive methods of continuous glucose monitoring available to them are not only painful, but also expensive. The technology being developed will provide accurate glucose measurement without the cost and pain associated with invasive methods.
The C8 MediSensors monitor employs Raman spectroscopy to trans-dermally measure the glucose level. The device emits a beam of light through the skin that calculates the Raman fingerprint of the molecule. The measurements taken by the optical glucose monitor are sent to the patient’s smartphone. The discrete glucose monitor is small enough to be worn around the abdomen using a band and is well hidden under the patient’s clothing. In addition to viewing the glucose level on the smartphone, the patient can access the measurement history of up to 4 months and download the data to the computer and share the readings with the care provider. The C8 MediSensors Optical Glucose Monitor can also be used to set hypo- and hyper-glycemic thresholds and set both audible and vibrating alarm settings.